Company is investigating efzofitimod in global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis patientsSAN DIEGO, Aug. 11, 2022 (GLOBE…
Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half…
CHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an…
Lead myotonic dystrophy type 1 (DM1) candidate continues to show promising preclinical data, including the pharmacokinetics (PK) and biodistribution data…
- Reported positive topline results from ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia patients; initiation of Phase…
WOBURN, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life…
-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including…
NEW YORK, NY, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading…
LONDON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it…
Phase 1 clinical trials of SZN-1326 and SZN-043 initiated and ongoingPreclinical proof-of-concept data for multiple programs presented and published in…